Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ERAS |
---|---|---|
09:32 ET | 10698 | 2.68 |
09:34 ET | 1800 | 2.685 |
09:36 ET | 700 | 2.68 |
09:38 ET | 60753 | 2.69 |
09:39 ET | 6218 | 2.68 |
09:41 ET | 8186 | 2.745 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Erasca Inc | 839.0M | -3.0x | --- |
Dianthus Therapeutics Inc | 850.1M | -4.9x | --- |
Arrivent Biopharma Inc | 798.0M | -9.4x | --- |
Perspective Therapeutics Inc | 884.7M | -9.0x | --- |
89Bio Inc | 898.1M | -3.7x | --- |
Annexon Inc | 760.7M | -5.1x | --- |
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $839.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 282.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.92 |
Book Value | $2.10 |
P/E Ratio | -3.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.